{"id":"NCT02764489","sponsor":"Baxalta now part of Shire","briefTitle":"FEIBA Reconstitution Volume Reduction and Faster Infusion Study (FEIBA STAR)","officialTitle":"A Phase 3b/4, Prospective, Multicenter, Open-label, Randomized, Crossover Study of Tolerability and Safety of FEIBA Reconstituted in Regular or 50% Reduced Volume and of Faster Infusion Rates in Patients With Hemophilia A or B With Inhibitors","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2019-02-12","primaryCompletion":"2021-12-27","completion":"2021-12-27","firstPosted":"2016-05-06","resultsPosted":"2023-02-09","lastUpdate":"2023-02-14"},"enrollment":45,"design":{"allocation":"RANDOMIZED","model":"CROSSOVER","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Hemophilia A or B With Inhibitors"],"interventions":[{"type":"BIOLOGICAL","name":"FEIBA","otherNames":["FEIBA NF.","AICC","anti-inhibitor coagulant complex","Anti-inhibitor Coagulant Complex Nanofiltered (activated prothrombin complex concentrate [APCC])","APCC","Activated prothrombin complex concentrate"]}],"arms":[{"label":"Part 1:FEIBA 85±15 U/kg at Regular Volume Then 50% Reduced Volume at 2 U/kg/min Rate or Vice Versa","type":"EXPERIMENTAL"},{"label":"Part 2:FEIBA 85±15U/kg 50% Reduced Volume at 4U/kg/min Rate Then at 10U/kg/min Rate","type":"EXPERIMENTAL"}],"summary":"The purpose of this study is to:\n\n* 1\\. To evaluate the tolerability and safety of infusing reduced volume Factor Eight Inhibitor Bypassing Activity (FEIBA) at the standard infusion rate of 2 U/kg/min\n* 2\\. To evaluate the tolerability and safety of infusing reduced volume FEIBA at increased rates of 4 and 10 U/kg/min, in comparison to the standard rate of 2 U/kg/min at the regular volume","primaryOutcome":{"measure":"Number of Participants With Any Treatment Emergent Adverse Event (TEAE)","timeFrame":"From first dose of study drug up to 7 days after the end of infusion (up to Day 41)","effectByArm":[{"arm":"Part 1:FEIBA 85 ± 15 U/kg Regular Volume at 2 U/kg/Min Rate","deltaMin":8,"sd":null},{"arm":"Part 1:FEIBA 85±15 U/kg 50% Reduced Volume at 2 U/kg/Min Rate","deltaMin":7,"sd":null},{"arm":"Part 2:FEIBA 85±15 U/kg 50% Reduced Volume at 4 U/kg/Min Rate","deltaMin":1,"sd":null},{"arm":"Part 2:FEIBA 85±15 U/kg 50% Reduced Volume at 10 U/kg/Min Rate","deltaMin":4,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":3,"countries":["Croatia","North Macedonia","Ukraine"]},"refs":{"pmids":[],"seeAlso":["https://clinicaltrials.takeda.com/study-detail/5f6b5fc34db2bf003ab459c3"]},"adverseEventsSummary":{"seriousAny":{"events":3,"n":33},"commonTop":["Arthralgia","Headache"]}}